OTR3® is a French biotech company that has developed a new class of therapeutic agents used for skin and corneal healing. The therapeutic approach, called "Matrix therapy" is based on RGTA® (ReGeneraTing Agents), engineered biodegradable sugar-based nano-polymers, mimicking heparan-sulfates.
After an injury, RGTA® target the wound, replace the degradated heparan-sulfates, bind to the proteins and growth factors and protect the matrix proteins from degradation. They restore the scaffold organization and the micro-environment of the cells allowing the tissue to rebuild.
OTR3 has placed on the market medical devices indicated for the treatment of hard to heal chronic cutaneous ulcers and corneal ulcers.
OTR3's Pipeline include innovative therapeutic products for ischemic stroke (Project awarded a H2020 SME Instrument grant), Acute respiratory distress syndrome (ARDS) and chronic ulcer for epidermolysis bullosa (Project awarded a PIA Leader Innov'Up grant).
Company Details
- Employees
- 23
- Address
- 4, Rue Française, Paris,75001,france
- Phone
- +33 (0)1 83 64 23 00
- co****@****tr3.com
- Industry
- Biotechnology
- Website
- otr3.com
- Keywords
- matrix therapy, healing, ReGeneraTing Agents, RGTA®, chronic wounds, corneal lesions, CACIPLIQ20®, CACICOL20®, Regenerative medicine, ischemic stroke, ARDS.
- HQ
- Paris
Otr3 Questions
Otr3's helpline number is +33 (0)1 83 64 23 00
Otr3's website is otr3.com
Otr3's LinkedIn profile is https://fr.linkedin.com/company/otr3
Otr3 has
23 employees.
View email and phone details for 23
employees at Otr3.
Otr3's industry is
Biotechnology
Otr3's top competitors are
Confidential Medical Practice,
Global Scar Society,
Osv Startup Program,
Projet 28,
Tibbiyah,
Wound Healing Society,
Etrs European Tissue Repair Society,
Biolamina,
Laprophan,
Servier.
Otr3's support email address is contact@otr3.com
Otr3's categories are Biotechnology
